<- Back to digest

JAAOS - 2026-10-15 - Journal Article; Multicenter Study

Risk of Overdose and Adverse Events With Concomitant Opioids and Gabapentinoid Use After Total Joint Arthroplasty.

Domingo PT, Berger GK, Gray P, Chaput R, Navarro R, Singh A

retrospective cohortLOE IIIn = 36,351N/A if not reported.

Topics

general
PMID: 42200647DOI: 10.5435/JAAOS-D-25-01651View on PubMed ->

Key Takeaway

In 36,351 opioid- and gabapentinoid-naïve TJA patients, concomitant low-dose gabapentinoids plus opioids did not significantly increase opioid-related overdose (0.07% vs 0.05%) or adverse events (0.45% vs 0.69%) compared with opioids alone.

Summary Depth

Choose how much analysis to show on this article page.

Summary

This multicenter retrospective cohort study compared safety outcomes in opioid- and gabapentinoid-naïve patients receiving opioids alone (n=29,009) versus opioids plus low-dose gabapentinoids (n=7,342) after TJA of the knee, hip, or shoulder between 2018 and 2024. Opioid-related overdose occurred in 0.05% of the opioids-alone group versus 0.07% in the combination group (P=0.3); ED or hospital admission for adverse events occurred in 0.69% versus 0.45%, respectively. No statistically significant difference was identified for any primary or secondary outcome.

Key Limitation

Only 19 total overdose events across 36,351 patients renders the study critically underpowered to detect a true difference in overdose risk, making the null finding for the primary outcome uninformative.

Original Abstract

PURPOSE

We evaluated the safety outcomes of opioids alone versus opioids plus low-dose gabapentinoids in patients naïve to both opioids and gabapentinoids, after total joint arthroplasty (TJA) of the knee, hip, or shoulder.

METHODS

This was a multicenter, population-based, retrospective cohort study based in a large, integrated health system. It included opioid-naïve and gabapentinoid-naïve patients who underwent TJA between 2018 and 2024. Patients were categorized into two groups: those dispensed opioids and low-dose gabapentinoids or those dispensed opioids alone postoperatively. The primary outcome was opioid-related overdose events. The secondary outcome was adverse events, including falls, fractures, neurologic/cognitive changes, sedation, and delirium.

RESULTS

In total, 36,351 consecutive patients comprised the study cohort, including 29,009 (79.8%) in the opioids-alone group and 7,342 (20.2%) in the opioids plus gabapentinoids group. In total, there were 19 (0.05% total cohort) opioid-related overdose events. Fourteen of these (0.05%) were in the opioids-alone group, and five (0.07%) were in the opioids plus gabapentinoids group ( P = 0.3). In addition, 233 patients (0.6%) experienced emergency department or hospital admission due to an adverse event, including 200 patients (0.69%) in the opioids-alone group and 33 patients (0.45%) in the opioids plus gabapentinoids group. No statistically significant difference in adverse event risk was identified between groups.

CONCLUSION

Concurrent prescriptions for opioids and low-dose gabapentinoids after TJA were not associated with a statistically significant difference in risk of emergency department or hospital readmission due to opioid-related overdose or adverse events compared with opioids alone. However, the rarity of overdose events limits statistical power, and these findings should be interpreted cautiously.